
Independent company · Cambridge, United States
Boltz
A public benefit company growing out of MIT research that develops biomolecular models, with open Boltz-2 and BoltzGen alongside proprietary ones.
Cambridge, United States
- Founded
- 2025
- Type
- Independent company
- Based in
- Cambridge, United States
- Featured projects
- 4
About
Boltz PBC builds AI models and infrastructure for biomolecular design and drug discovery. Its platform, Boltz Lab, lets scientists design small molecules and biologics.
Its open-source models include Boltz-2 and BoltzGen, while BoltzProt-1 and BoltzMol-1 are proprietary. The site reports more than 5 million downloads and over 1,000 companies using its tools, and announced an agreement with Bristol Myers Squibb in October 2026.
Mission and ambitionsBoltz aims to make biomolecular modelling broadly available while building a commercial platform on top.
Known for
- 01
Boltz-1 and Boltz-2 open biomolecular models
- 02
BoltzGen design model
- 03
Boltz Lab platform
Milestones
- 2024
Boltz-1 released
The first open model from the MIT group, released in late 2024.
- 2025
Boltz-2 released
A model that jointly predicts complex structure and binding affinity.
- 2026
Seed round and Pfizer collaboration
Boltz PBC launched with a 28 million dollar seed round alongside Boltz Lab and a Pfizer collaboration.
- 2026
Bristol Myers Squibb agreement
An agreement to deploy biomolecular AI models for drug discovery.
Open source
Official Boltz repository
Fast protein structure prediction
Notable releases
Openness
MIT-licensed code and weights.
People
- Gabriele CorsoCo-founder and CEO
Previously at MIT CSAIL.
- Jeremy WohlwendCo-founder and CTO
Maintains the Boltz repository.
Listed from the lab's own pages and public profiles.
Contact and community
Via website.
Sources
Compiled from the lab's public pages, Hugging Face and GitHub. Last checked 2026-11-17. Something wrong or out of date? Tell us on Discord.



